Impact of 18 FDG-Avidity and Immunosuppression on Idiopathic and Genetic Cardiomyopathies
Circulation: Cardiovascular Imaging · 13.10.2026
DOI: 10.1161/circimaging.126.019970 ↗Kurz gefasst
Fachartikel in der Zeitschrift Circulation: Cardiovascular Imaging, online erschienen am 13.10.2026. Verfasst von Shiva Tabaghi und 15 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiology, University of Washington, Seattle (S.T., G.H.B., N.C., R.K.C., A.S.-O., B.N.). Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS.
Abstract (Originalsprache)
BACKGROUND: Myocardial 18 fluorodeoxyglucose ( 18 FDG)-avidity is frequently seen in patients with genetic cardiomyopathy, as well as a growing “idiopathic 18 FDG-avidity” group of genotype-negative patients who do not clearly have cardiac sarcoidosis. The prognostic implications of 18 FDG-avidity in patients with and without genetic cardiomyopathy, and the effects of immunosuppression in the latter, remain uncertain. METHODS: This multicenter, retrospective study included all patients who were referred for both 18 FDG-PET and cardiomyopathy genetic testing. Patients with acute myocarditis, biopsy-proven sarcoidosis, or extracardiac 18 FDG-avidity were excluded. We investigated heart failure (HF) composite (left ventricular assist device, heart transplant, HF hospitalization, or death) and arrhythmia composite (sustained ventricular arrhythmias [ventricular tachycardia/VF], atrioventricular block, or death) outcomes using survival analysis, including Cox proportional hazards modeling and inverse probability of treatment weighting. RESULTS: Among 372 patients, 142 (38%) were 18 FDG-avid. The prevalence of genetic cardiomyopathy among 18 FDG-avid patients (12%) was similar to that of 18 FDG-negative patients (18%; P =0.11). Unadjusted, 18 FDG-avidity was associated with an increased risk of HF composite (hazard ratio, 1.69 [95% CI, 1.04–2.75]; P =0.034) and arrhythmia composite (hazard ratio, 1.63 [95% CI, 1.1–2.4]; P =0.014) outcomes compared with 18 FDG-negative patients. However, these associations were not statistically significant after multivariable adjustment, nor were there significant differences in 18 FDG-associated risks in patients with genetic cardiomyopathy versus genotype-negative patients. After inverse probability of treatment weighting, immunosuppression of 18 FDG-avid patients (n=49) was not associated with a reduction in HF or arrhythmia composite outcomes compared with those who were not immunosuppressed (n=93). CONCLUSIONS: Myocardial-only 18 FDG-avidity is not significantly associated with HF or arrhythmia risk in patients who do not clearly have cardiac sarcoidosis (including those with genetic cardiomyopathy). Immunosuppression therapy does not seem to modify the disease course, suggesting that not all myocardial 18 FDG uptake reflects clinically significant inflammation.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Cardiology, University of Washington, Seattle (S.T., G.H.B., N.C., R.K.C., A.S.-O., B.N.).
- Division of Cardiovascular Diseases and Hypertension, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ (S.H.).
- Division of Cardiology, Heart and Vascular Institute, Mass General Brigham, Brigham and Women's Hospital, Boston, MA (E.D.G., N.K.L., R.B., M.F.D.C., S.D.).
- Knight Cardiovascular Institute, Oregon Health & Science University, Portland (M.L., M.P., B.L.).
- Department of Biobehavioral Nursing and Health Informatics, University of Washington School of Nursing, Seattle (A.V.).
ORCID-Profile: Shiva Tabaghi, Stephen Hankinson, Esra D Gumuser, Madison Pico, Neal Chatterjee, Alexi Vasbinder, Richard K Cheng, April Stempien-Otero, Neal K Lakdawala, Ron Blankstein, Marcelo F Di Carli, Benjamin Levin, Sanjay Divakaran, Babak Nazer
Förderung
- NHLBI NIH HHS
Zitieren
APA
Tabaghi, S., Bevan, G. H., Hankinson, S., Gumuser, E. D., Lal, M., Pico, M., Chatterjee, N., Vasbinder, A., Cheng, R. K., Stempien-Otero, A., Lakdawala, N. K., Blankstein, R., Di Carli, M. F., Levin, B., Divakaran, S., & Nazer, B. (2026). Impact of 18 FDG-Avidity and Immunosuppression on Idiopathic and Genetic Cardiomyopathies. Circulation: Cardiovascular Imaging. https://doi.org/10.1161/circimaging.126.019970
Vancouver
Tabaghi S, Bevan GH, Hankinson S, Gumuser ED, Lal M, Pico M, et al. Impact of 18 FDG-Avidity and Immunosuppression on Idiopathic and Genetic Cardiomyopathies. Circulation: Cardiovascular Imaging. 2026. doi:10.1161/circimaging.126.019970
BibTeX
@article{Tabaghi2026,
author = {Tabaghi, Shiva and Bevan, Graham H and Hankinson, Stephen and Gumuser, Esra D and Lal, Mallika and Pico, Madison and Chatterjee, Neal and Vasbinder, Alexi and Cheng, Richard K and Stempien-Otero, April and Lakdawala, Neal K and Blankstein, Ron and Di Carli, Marcelo F and Levin, Benjamin and Divakaran, Sanjay and Nazer, Babak},
title = {Impact of 18 FDG-Avidity and Immunosuppression on Idiopathic and Genetic Cardiomyopathies},
journal = {Circulation: Cardiovascular Imaging},
year = {2026},
doi = {10.1161/circimaging.126.019970}
}
EUVIMED